Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
纳武利尤单抗治疗复发/难治性经典型霍奇金淋巴瘤:关键性 II 期 CheckMate 205 研究的 5 年生存率
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2023010334
Ansell, Stephen M; Bröckelmann, Paul J; von Keudell, Gottfried; Lee, Hun Ju; Santoro, Armando; Zinzani, Pier Luigi; Collins, Graham P; Cohen, Jonathon B; de Boer, Jan Paul; Kuruvilla, John; Savage, Kerry J; Trněný, Marek; Provencio, Mariano; Jäger, Ulrich; Willenbacher, Wolfgang; Wen, Rachael; Akyol, Alev; Mikita-Geoffroy, Joanna; Shipp, Margaret A; Engert, Andreas; Armand, Philippe